Inhibitor of bruton's tyrosine kinase
US10112922B2 · kind B2 · utility
2Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 7, 2015 |
| Grant date | Oct 30, 2018 |
| Priority date | — |
| Expiry date | May 7, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.